文献速递脊柱外科

贝佐特明α(重组人骨形态发生蛋白-6)在后路腰椎椎间融合术中的应用:一项随机、双盲、安慰剂对照的2期研究

Bezeotermin Alfa (rhBMP-6) Administration in Lumbar Interbody Fusion Surgery Using a Posterior Approach: A Randomized, Double-Blinded, Placebo-Controlled Phase-2 Study.
PubMed 文献 · J Bone Joint Surg Am · 2025-11-17

这项前瞻性、多中心、随机、双盲、安慰剂对照2期试验在中国6个中心纳入63例因退行性椎间盘疾病行L3至S1单节段后路腰椎椎间融合术的成人患者,按1:1:1随机接受安慰剂、0.25 mg或0.5 mg贝佐特明α(重组人骨形态发生蛋白-6,rhBMP-6,曾称AGA111),随访12个月。主要终点为不良事件的发生率;所有患者均报告至少1例不良事件,多数为轻至中度,贝佐特明组未报告药物相关严重不良事件。贝佐特明组从第3个月至第12个月在影像学融合成功率及ODI和VAS评分改善方面均呈现高于安慰剂组的趋势。

要点

  • 所有患者均报告至少1例不良事件,多数为轻至中度,贝佐特明组未报告药物相关严重不良事件。
  • 贝佐特明组从第3个月至第12个月影像学融合成功率及ODI、VAS评分改善呈现高于安慰剂组的趋势。
  • 贝佐特明/自体血凝块在后路单节段腰椎椎间融合术中安全且耐受良好,初步疗效支持其进一步临床开发。

核心结论

  • 贝佐特明/自体血凝块在后路单节段腰椎椎间融合术中安全且耐受良好,其加速脊柱融合和改善临床结局的初步疗效支持进一步临床开发。

研究设计与样本

  • 前瞻性、多中心、随机、双盲、安慰剂对照2期试验,在中国6个临床中心纳入63例因退行性椎间盘疾病行L3至S1单节段择期后路腰椎椎间融合术的成人患者,按1:1:1随机分配至安慰剂组、0.25 mg贝佐特明组或0.5 mg贝佐特明组,随访12个月。

主要发现

  • 所有患者在研究期间均报告至少1例不良事件,但大多数不良事件为轻至中度。
  • 贝佐特明组未报告药物相关严重不良事件。
  • 从第3个月至第12个月,贝佐特明组影像学融合成功率及ODI和VAS评分改善呈现高于安慰剂组的趋势。

关键数值与推荐

  • 主要终点为不良事件的发生率。
  • 次要终点包括抗rhBMP-6抗体、影像学融合成功率、Oswestry功能障碍指数(ODI)评分变化、视觉模拟量表(VAS)疼痛评分变化及血清药物浓度。
  • 安慰剂组、0.25 mg贝佐特明组和0.5 mg贝佐特明组分别有21例、20例和22例患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel osteoconductive and osteoinductive therapies for posterior-based lumbar interbody fusion surgery are needed. Bezeotermin alfa (recombinant human bone morphogenetic protein [rhBMP]-6, previously referred to as AGA111) is a potential potent stimulator of bone regeneration. This prospective, multicenter, randomized, double-blinded, placebo-controlled Phase-2 trial evaluated the safety and preliminary efficacy of bezeotermin carried by autologous blood coagulum (ABC) in patients undergoing lumbar interbody fusion surgery between L3 and S1 for degenerative disc disease. METHODS: Adult patients scheduled for single-level elective lumbar interbody fusion surgery across 6 clinical trial sites in the People's Republic of China were randomized 1:1:1 to placebo, 0.25 mg bezeotermin, or 0.5 mg bezeotermin and followed for 12 months. The primary end point was the incidence of adverse events (AEs). Secondary end points included anti-rhBMP-6 antibodies, the success rate of radiographic fusion, changes in the Oswestry Disability Index (ODI) score, changes in the pain score on a visual analogue scale (VAS), and serum drug concentrations. RESULTS: Sixty-three patients with a mean age of 59.2 years (52% female, 98.4% Han) were enrolled in the study. Twenty-one, 20, and 22 of the patients were randomized to placebo, 0.25 mg bezeotermin, and 0.5 mg bezeotermin, respectively. All patients reported at least 1 AE during the study, but most AEs were mild to moderate in severity. No drug-related serious AEs were reported in the bezeotermin groups. There was a trend toward a higher rate of successful radiographic fusion and greater improvement of the ODI and VAS scores in the bezeotermin groups than in the placebo group from month 3 to month 12. CONCLUSIONS: This prospective, randomized, double-blinded, placebo-controlled trial demonstrated that bezeotermin/ABC was safe and well tolerated during posterior-based single-level lumbar interbody fusion. The preliminary efficacy of bezeotermin in accelerating spinal fusion and improving clinical outcomes supports its further clinical development. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Li W, Luo X, Zhou X, et al. Bezeotermin Alfa (rhBMP-6) Administration in Lumbar Interbody Fusion Surgery Using a Posterior Approach: A Randomized, Double-Blinded, Placebo-Controlled Phase-2 Study. J Bone Joint Surg Am. 2025. PMID: 41405575. doi:10.2106/JBJS.25.00424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。